Changes in Optical Coherence Tomography Leakage Mapping in Diabetic Macular Edema After Conbercept Treatment

Study Overview
=================
Brief Summary
-----------------
Eyes with diabetic macular edema requiring conbercept treatment will be followed up for one month. Before treatment, one week after treatment and one month after treatment, the eyes will be examined by optical coherence tomography (OCT) and optical coherence tomographic angiography (OCTA). The changes of macular edema will be observed and analyzed by OCT leakage mapping software, and the relationship between the changes of macular edema and visual acuity will be analyzed.

Detailed Description
-----------------
Research purpose: After one month follow-up, we will observe whether OCTleakage mapping can be used as a biomarker to predict the prognosis of DME eyes, and will observe the effect of Conbercept on improving edema and visual acuity of DME eyes. Subjects Number of subjects planned to be recruited: 35 Inclusion criteria: Age ≥ 18 Diabetic macular edema eyes treated with conbercept for the first time in 1 week Informed consent of patients and signing of informed consent Exclusion criteria: High myopia Macular diseases affecting vision Vitreous hemorrhage requiring surgery Patients with anterior segment neovascularization Eye or periocular infection Optic neuropathy and glaucoma Periphlebitis, ophthalmic ischemic syndrome, uveitis, coat's disease, FEVR and other retinal diseases Ametropia and cataract surgery In 3 months, in addition to this treatment of conbercept, other anti VEGF treatment, laser treatment or vitreoretinal surgery were performed Other systemic diseases can not complete follow-up

Official Title
-----------------
Changes in Optical Coherence Tomography Leakage Mapping in Diabetic Macular Edema Before and After Treatment With Conbercept

Conditions
-----------------
Diabetic Macular Edema

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1）Age ≥ 18 2) Diabetic macular edema eyes treated with conbercept for the first time in 1 week 3) Informed consent of patients and signing of informed consent Exclusion Criteria: 1）Myopia ≥ 6.0D 2) Macular diseases affecting vision 3) Vitreous hemorrhage requiring surgery 4) Patients with anterior segment neovascularization 5) Eye or periocular infection 6) Optic neuropathy and glaucoma 7) Periphlebitis, ophthalmic ischemic syndrome, uveitis, coat's disease, FEVR and other retinal diseases 8) Ametropia and cataract surgery 9) In 3 months, in addition to this treatment of conbercept, other anti VEGF treatment, laser treatment or vitreoretinal surgery were performed 10) Other systemic diseases can not complete follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| central retinal thickness（CRT） | CRT will be measured by OCT software and the changes before treatment, 1 week after treatment and 1 month after treatment will be compared | 2020-12 | 
| best corrected visual acurity(BCVA) | Compare the changes of BCVA before treatment, 1 week after treatment and 1 month after treatment | 2020-12 | 
| low optical ratio(LOR) | The image will be processed by OCT leakage mapping software, and the changes of LOR will compared before treatment, 1 week after treatment and 1 month after treatment | 2020-12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ellipsoid Zone | The continuity of EZ will be judged by OCT image processing, and the changes before treatment, 1 week after treatment and 1 month after treatment will be compared | 2020-12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diebetic macular edema, optical coherence tomography, conbercept